Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Summary: The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26–29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I–III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2‐deoxy‐d‐glucose, everolimus, fenfluramine, huperzine A, minocycline,SAGE‐217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives,sec‐butylpropylacetamide,FV‐082, 1 OP‐2198,NAX 810‐2, and SAGE‐689). Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AED s with potentially improved therapeutic profiles compared with existing agents. Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000 · cited 2×
“Various reports have shown effects and others no effect at all.(63) A recent Cochrane review on cannabinoids for treatment of epilepsy concluded that there was not enough data to draw conclusions and that more research was necessary to determine if they may be efficacious in the treatment of epilepsy.”
BackgroundDe Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng, L., Xu, L., Gutmann, D. H., & Wong, M. (2008) · Annals of Neurology · doi:10.1002/ana.21331 · Cited by 639 · cited 3×
“Early treatment with sirolimus could prevent seizure onset and premature death, and reverse astrogliosis and neuronal disorganization.(105)”
BackgroundResultInfluentialRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Stein, M., Lin, H., Jeyamohan, C., Dvorzhinski, D., Gounder, M., Bray, K., Eddy, S., Goodin, S., White, E., & DiPaola, R. S. (2010) · The Prostate · doi:10.1002/pros.21172 · Cited by 291
Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites
Raab-Graham, K. F., Haddick, P. C. G., Jan, Y. N., & Jan, L. Y. (2006) · Science · doi:10.1126/science.1131693 · Cited by 267 · cited 1×
“1 expression in cortical and hippocampal neurons.(114,115) Chronic sirolimus administration also increases GABA receptor–mediated synaptic activity and reduces AMPA receptor surface expression.”
BackgroundProgress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.10.001 · Cited by 243 · cited 1×
“The antiseizure activity of NAX 810-2 has been described previously.(2,3) More recently, NAX 810-2 has been found to potently protect”
BackgroundSelf-citationOpen-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 1×
“Similarly, short-term treatment with minocycline was reported to be associated with improved communication and attention, and reduced anxiety in young adults with fragile X syndrome.(161) These studies raise a possibility of future use of minocycline as a potential disease-modifying agent not only to block epileptogen…”
BackgroundSuccessful use of fenfluramine as an add‐on treatment for Dravet syndrome
Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P. G., & Lagae, L. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03495.x · Cited by 210 · cited 2×
“patient, and topiramate and a benzodiazepine in six patients.(141) At the time of initiation of fenfluramine, the mean age of this cohort was 8 years (median = 7 years; range 1.”
BackgroundMethodNicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., et al. (2016) · Epilepsia · doi:10.1111/epi.13267 · Cited by 169 · cited 2×
“Supportive positron emission tomography (PET) studies in rhesus monkeys reported estimated half-times for brain occupancy of SV2A of approximately 3 and 23 min for brivaracetam and levetiracetam, respectively, after intravenous administration.(21)”
BackgroundKlitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Cited by
Kossoff, E. H., Zupec‐Kania, B. A., Auvin, S., Ballaban‐Gil, K. R., Christina Bergqvist, A. G., Blackford, R., Buchhalter, J. R., Caraballo, R. H., Cross, J. H., Dahlin, M. G., et al. (2018) · Epilepsia Open · doi:10.1002/epi4.12225 · Cited by 768
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Martinez Botella, G., Salituro, F. G., Harrison, B. L., Beresis, R. T., Bai, Z., Blanco, M.-J., Belfort, G. M., Dai, J., Loya, C. M., Ackley, M. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00846 · Cited by 129
Targeting Kv7 Potassium Channels for Epilepsy
Perucca, E., & Taglialatela, M. (2025) · CNS Drugs · doi:10.1007/s40263-024-01155-3 · Cited by 43
Self-citationGrupe, M., Bentzen, B. H., Benned-Jensen, T., Nielsen, V., Frederiksen, K., Jensen, H. S., Jacobsen, A.-M., Skibsbye, L., Sams, A. G., Grunnet, M., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173440 · Cited by 19
Metadata
- Authors
- Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2017-01-23
- Volume
- 58
- Issue
- 2
- Pages
- 181-221
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2580388554
- Cited by
- 110
- References
- 15
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.